Tom Luedde graduated from Medizinische Hochschule Hannover, Germany, and was trained and board certified at University Hospital RWTH Aachen, Germany, in Internal Medicine, Gastroenterology/Hepatology, Intensive Care Medicine and Infectious Diseases. He was a research fellow at the Lineberger Cancer Centre, UNC North Carolina, USA (2000) and a Postdoc at the European Molecular Biology Laboratory and the University of Cologne, Department of Mouse Genetics, Germany (2005-2007). In 2014, he received the Mildred-Scheel Endowed Professorship from the German Cancer Foundation. Since 2020, he has been the director of the department of Gastroenterology, Hepatology and Infectious Diseases at the University Hospital Duesseldorf/Germany.
His research focusses on the role of inflammatory signaling and cell death in the development of liver cancer on the basis of NASH. The focus of his clinical research is on biomarkers and artificial intelligence in gastrointestinal tumors, and health services research on patients with gastrointestinal diseases and liver transplantation. He held an ERC Starting grant and currently holds an ERC Consolidator Grant on the pathophysiology of liver cancer development. He served as associate editor of CMGH from 2019-2021 and currently serves as associate editor at the Journal of Hepatology.